Daily pill can double survival time for world’s deadliest cancer, trial shows
Summary
A new daily pill called daraxonrasib can double the survival time for patients with advanced pancreatic cancer, according to a clinical trial involving 500 patients. The drug works by blocking a cancer-causing protein called Kras and showed better results and fewer side effects than chemotherapy.Key Facts
- Pancreatic cancer is one of the deadliest cancers and is often diagnosed late when it has spread.
- Daraxonrasib targets the Kras protein, which is present in over 90% of common pancreatic cancer cases.
- In the trial, patients taking daraxonrasib lived on average 13.2 months versus about 6.6 months for those receiving chemotherapy.
- The drug works by shutting down Kras regardless of the specific gene mutation variant.
- Experts called this treatment a major breakthrough and the first effective targeted therapy for pancreatic cancer.
- The trial was presented at the American Society of Clinical Oncology’s annual meeting.
- Daraxonrasib caused fewer side effects compared to traditional chemotherapy.
- Patient advocates described these results as offering new hope for a disease with historically low survival rates.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
